Barrett’s Esophagus Test Identifies High-Risk Patients Missed by Standard Pathology
A study of 85 patients shows the TissueCypher test detected 15% with elevated cancer progression risk despite a non-dysplastic diagnosis.
Category: Uncategorized
Uncategorized
Latest
Uncategorized
Latest
Color Health Partners with CDC to Increase Access to COVID Testing
Color Health is providing free COVID testing through the CDC's Increasing Community Access to Testing program.
Uncategorized
Latest
Ortho Clinical Diagnostics, Thermo Fisher Scientific Partner on QC Solutions
Ortho Clinical Diagnostics has a distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's Vitros QC Solutions to Vitros System customers worldwide.
Clinical Chemistry
Latest
New AAV Quantification Kits Aim to Simplify Gene Therapy Laboratory Workflows
The ready-to-use kits provide broad serotype coverage, standardized reagents, and simplified workflows for laboratories measuring adeno-associated virus capsids.
Flow Cytometry
Latest
New Infrared Dye Antibody Conjugates Enable Expanded Flow Cytometry Panel Design
The infrared dye antibody conjugates aim to expand human phenotyping experiments innovation and make high-parameter flow cytometry more accessible.
Mass Spectrometry
Latest
Oxford Instruments Launches 90 MHz Benchtop NMR Spectrometer
The X-Pulse 90 is designed to deliver enhanced sensitivity and faster data collection.
Immunoassay
Latest
Lateral Flow Assays Market Projected to Reach $12.1 Billion by 2030
Market growth driven by expanding clinical applications and regulatory innovation, with kits and reagents dominating product segments.
Molecular Diagnostics
Latest
New qPCR Multiplexing Probes Aim to Reduce Turnaround Times and Streamline Ordering
The probes allow up to 5-plex multiplexing and are paired with a modernized online tool for ordering qPCR components.
Point-of-Care
Latest
Phase 2B COPD Trial to Use Point-of-Care Test for Rhinovirus Detection
The phase 2B trial of vapendavir will use bioMérieux’s Biofire Spotfire panel—a CLIA-waived molecular test that detects rhinovirus—to confirm infections in COPD patients.